U.S. License Holder:
Date of License:
HERCEPTIN HYLECTA (trastuzumab; hyaluronidase-oysk) is a combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase, indicated in adults for:
The treatment of HER2-overexpressing breast cancer.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
7,625,558 (Compositions and Methods of Treating Tumors)
Trustees of The University of Pennsylvania